Figure 8 depicts the effect of COMPOUND I on Ras downstream Signalling

Figure 9 depicts the effect of COMPOUND I on inhibition of the Ras-GTP complex

Figure 10 depicts the 1H NMR spectra of the compound I of the present invention

Figure 11 depicts the 13CNMR Spectra of the compound I of the present invention

Figure 12 depicts the 2D COSY Spectrum of the compound I of the present invention

Figure 13 depicts the IR Spectrum of the compound I of the present invention

SUMMARY:

The present disclosure discloses a anticancer activity exhibiting compound of structural formula I :



Formula I

or a pharmaceutically acceptable salt thereof; in which

- W is selected from a group comprising of substituted saturated/unsaturated branched/linear aliphatic amine, substituted aromatic amine, unsubstituted saturated/unsaturated branched/linear aliphatic amine, unsubstituted aromatic amine;

- X is selected from a group comprising of H, substituted/unsubstituted saturated/unsaturated branched/linear aliphatic alkyl group with atleast one carbon atom, substituted/unsubstituted saturated/unsaturated branched/linear aliphatic alkoxy group with atleast one carbon atom, substituted/unsubstituted aryl group, substituted/unsubstituted aryloxy group;
- Y is selected from a group comprising of H, substituted/unsubstituted saturated/unsaturated branched/linear aliphatic alkyl group bonded to a carbonyl group, substituted/unsubstituted aryl group bonded to a carbonyl group;
- Z is selected from a group comprising of H, OH.

In an aspect, there is provided a compound of structural formula I:



Formula I

or a pharmaceutically acceptable salt thereof; wherein

W is selected from a group comprising of substituted saturated/unsaturated branched/linear aliphatic amine, substituted aromatic amine, unsubstituted saturated/unsaturated branched/linear aliphatic amine, unsubstituted aromatic amine;

X is selected from a group comprising of H, substituted/unsubstituted saturated/unsaturated branched/linear aliphatic alkyl group with at least one carbon atom, substituted/unsubstituted saturated/unsaturated branched/linear aliphatic alkoxy group with at least one carbon atom, substituted/unsubstituted aryl group, substituted/unsubstituted aryloxy

group;

Y is selected from a group comprising of H, substituted/unsubstituted saturated/unsaturated branched/linear aliphatic alkyl group bonded to a carbonyl group, substituted/unsubstituted aryl group bonded to a carbonyl group;

Z is selected from a group comprising of H, OH.

In another aspect, there is provided a pharmaceutical composition comprising a therapeutically effective amount of compound as described herein, or a therapeutically effective amount of pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

In another aspect, there is provided a pharmaceutical composition comprising a therapeutically effective amount of compound comprising structure of compound I



Compound I,

and a pharmaceutically acceptable carrier.

DETAILED DESCRIPTION OF THE INVENTION:

DEFINITIONS:

Alkyl" means saturated carbon chains which may be linear or branched or

combinations thereof, unless the carbon chain is defined otherwise. Other groups having the prefix “alk”, such as alkoxy and alkanoyl, also may be linear or branched, or combinations thereof, unless the carbon chain is defined otherwise. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec- and tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, and the like. In one embodiment of the present invention, alkyl is methyl.

“Aryl” means a monocyclic, bicyclic or tricyclic carbocyclic aromatic ring or ring system containing 5-14 carbon atoms, wherein at least one of the rings is aromatic. Examples of aryl include phenyl and naphthyl. In one embodiment of the present invention, aryl is phenyl.